Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
Nemolizumab improves skin lesions, itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis: Results from two identical phase 3 multinational studies (ARCADIA 1 and ARCADIA 2)
book_2
Source:
EADV Congress 2023 - Oral session
calendar_today
Published on Medfyle:
October 2023
import_contacts
6
min
In this medfyle
Itch is one of the most important symptoms for patients with atopic dermatitis. The ARCADIA trials explored the impact of nemolizumab on itch and sleep. Results presented at EADV 2023 show rapid and sustained results.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the EADV Congress 2023. The content is developed by Infomedica in collaboration with the EADV.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, or the EADV.
©2023 Infomedica. All rights reserved.
